Načítá se...
Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
PURPOSE: Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide...
Uloženo v:
| Vydáno v: | J Clin Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Clinical Oncology
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4979191/ https://ncbi.nlm.nih.gov/pubmed/19652059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.7356 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|